IRulya Therapeutics Inc. (IRLA) stock
IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$38.45+1.09 (+2.92%)
Close on Nov 17, 2026Market cap $39.11MP/E –Yield –
IRulya Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
IRulya Therapeutics's price to book ratio was 20.6× on Jul 31, 2026, against 42.3× a year earlier. Over the last 5 years it ranged from 4.4× to 402.0×, with a median of 18.6×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Jul 31, 2026 | 20.6× | −130.2 |
| 2025 | Oct 31, 2025 | 150.8× | +114.8 |
| 2024 | Dec 31, 2024 | 36.0× | +26.8 |
| 2023 | Dec 29, 2023 | 9.2× | +4.8 |
| 2022 | Dec 30, 2022 | 4.4× | −52.4 |
| 2021 | Dec 31, 2021 | 56.8× | −30.3 |
| 2020 | Dec 31, 2020 | 87.2× | −149.6 |
| 2019 | Dec 31, 2019 | 236.8× | – |
See a number that looks wrong?